Literature DB >> 7604530

Effective immune protection of pigs against cysticercosis.

E Nascimento1, J O Costa, M P Guimarães, C A Tavares.   

Abstract

A scolex protein antigen (SPA) was prepared from cysticerci of Taenia solium obtained from naturally infected pigs. Yorkshire pigs were vaccinated with SPA plus incomplete Freund's adjuvant (IFA) or with SPA plus Corynebacterium parvum (CP). Controls were given IFA plus phosphate-buffered saline (PBS) or CP plus PBS. All animals were given three subcutaneous injections at 20-day intervals. Ten days after the third injection, the pigs were fed with 10(4) viable eggs of T. solium. All pigs developed a delayed type hypersensitivity, and a transient eosinophilia after the first dose of vaccine. High titers of specific antibodies were detected in the sera of vaccinated animals and in infected controls. A protection level of 71.43% was recorded in animals vaccinated with SPA plus IFA and of 75.00% in those vaccinated with SPA plus CP.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7604530     DOI： 10.1016/0165-2427(94)05327-o

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN： 0165-2427            Impact factor:   2.046


  7 in total

1.  Towards a Taenia solium cysticercosis vaccine: an epitope shared by Taenia crassiceps and Taenia solium protects mice against experimental cysticercosis.

Authors:  A Toledo; C Larralde; G Fragoso; G Gevorkian; K Manoutcharian; M Hernández; G Acero; G Rosas; F López-Casillas; C K Garfias; R Vázquez; I Terrazas; E Sciutto
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  The highly antigenic 53/25 kDa Taenia solium protein fraction with cathepsin-L like activity is present in the oncosphere/cysticercus and induces non-protective IgG antibodies in pigs.

Authors:  Mirko Zimic; Mónica Pajuelo; Robert H Gilman; Andrés H Gutiérrez; Luis D Rueda; Myra Flores; Nancy Chile; Manuela Verástegui; Armando Gonzalez; Héctor H García; Patricia Sheen
Journal:  Vet Immunol Immunopathol       Date:  2011-11-11       Impact factor: 2.046

3.  Immunotherapy for porcine cysticercosis: implications for prevention of human disease. Cysticercosis Working Group in Peru.

Authors:  C A Evans; A E Gonzalez; R H Gilman; M Verastegui; H H Garcia; A Chavera; J B Pilcher; V C Tsang
Journal:  Am J Trop Med Hyg       Date:  1997-01       Impact factor: 2.345

4.  Heterologous prime-boost oral immunization with GK-1 peptide from Taenia crassiceps cysticerci induces protective immunity.

Authors:  Gladis Fragoso; Fernando Esquivel-Guadarrama; M Angélica Santana; Raul J Bobes; Beatriz Hernández; Jacquelynne Cervantes; René Segura; Fernando A Goldbaum; Edda Sciutto; Gabriela Rosas
Journal:  Clin Vaccine Immunol       Date:  2011-05-18

5.  Two epitopes shared by Taenia crassiceps and Taenia solium confer protection against murine T. crassiceps cysticercosis along with a prominent T1 response.

Authors:  A Toledo; G Fragoso; G Rosas; M Hernández; G Gevorkian; F López-Casillas; B Hernández; G Acero; M Huerta; C Larralde; E Sciutto
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Characterization of S3Pvac anti-cysticercosis vaccine components: implications for the development of an anti-cestodiasis vaccine.

Authors:  Dunia Rassy; Raúl J Bobes; Gabriela Rosas; Victor H Anaya; Klaus Brehm; Beatriz Hernández; Jacquelynne Cervantes; Saúl Pedraza; Julio Morales; Nelly Villalobos; Aline S de Aluja; Juan P Laclette; Caris M Nunes; Germano F Biondi; Gladis Fragoso; Marisela Hernández; Edda Sciutto
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

Review 7.  Managing neurocysticercosis: challenges and solutions.

Authors:  Yannick Fogoum Fogang; Abdoul Aziz Savadogo; Massaman Camara; Dènahin Hinnoutondji Toffa; Anna Basse; Adjaratou Djeynabou Sow; Mouhamadou Mansour Ndiaye
Journal:  Int J Gen Med       Date:  2015-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.